NCT02658929: Phase 1 - Study of bb2121 in BCMA-Expressing refractory Multiple Myeloma CRB-401

CRB-401

NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma

NCT02658929: Phase 1: Study of bb2121 in Multiple Myeloma

Study CRB-401 is a 2-part, non-randomized, open label, multi-site Phase 1 study of bb2121 in adults with relapsed/refractory multiple myeloma (MM). Experimental: bb2121 - bb2121 autologous CAR T cells will be infused at a dose ranging from 150 - 450 x 10^6 CAR+ T cells after receiving lymphodepleting chemotherapy.

This is a 2-part, non-randomized, open label, multi-site Phase 1 study. the study design consists of 2 parts: Part A (Dose Escalation), in which the RP2D is determined, and Part B (Expansion Cohorts), in which subjects are treated with the determined RP2D.

Sponsor

Celgene

Collaborator

bluebird bio

---

ClinicalTrials.gov Identifier: NCT02658929

Official Title: CRB-401 A Phase 1 Study of bb2121 in BCMA-Expressing Multiple Myeloma